Filed under: Newsletters, Amgen Inc (AMGN), Bargain stocks, Stocks to Buy
“While the stock has rebounded a bit from its August lows, we view this as a great opportunity to buy Amgen (NASDAQ: AMGN), one of the premier names in a key industry,” says George Putnam.
In his The Turnaround Letter, he explains, “An interesting list of value investors, including David Dreman and Bill Miller, have accumulated the stock. We recommend joining them.” Here is his review.
“Deriving its name from Applied Molecular Genetics, Amgen began in the early 1980s developing products based on advances in recombinant DNA and molecular biology. The company’s Epogen and Neupogen products became the biotech industry’s first two blockbuster therapies.
“Today, Amgen is the world’s largest biotechnology company. From its IPO in 1984, the stock went on a 16-year run from a split adjusted $0.08 to over $80 by late 2000! But Amgen’s revenue growth rate slowed following the turn of the century, and investors began lowering the premium they were willing to pay for the stock.
“More recently, investors were spooked by regulatory questions about two of the company’s key drugs Epogen ($2.5 billion in 2006 sales) and Aranesp ($4.1 billion). As a result, in August the stock dropped below 50 for the first time since early 2003.
Continue reading Amgen (AMGN): Turnaround guru sees ‘great opportunity’
Permalink | Email this | Comments
Entries (RSS)